Plus Therapeutics Inc (PSTV)

$0.66 +0.06 (9.75%)
Market Cap 81.08M
Revenue (ttm) 5.82M
Net Income (ttm) -12.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1.30
Profit Margin -223.02%
Debt to Equity Ratio 0.00
Volume 9,071,711
Avg Vol 22,174,209
Day's Range N/A - N/A
Shares Out 137.43M
Stochastic %K 78%
Beta 0.82
Analysts Strong Sell
Price Target $7.25

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 255 7194
Fax: 210 974 6901
Address:
2710 Reed Road, Suite 160, Houston, United States
GoldenBullys
GoldenBullys Dec. 4 at 10:10 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $PSTV $VALE $CSIQ $HON 5
0 · Reply
BennaG
BennaG Dec. 4 at 10:03 PM
$PSTV
0 · Reply
Mapagotrades
Mapagotrades Dec. 4 at 10:02 PM
$PSTV 😊😊😅
0 · Reply
Mapagotrades
Mapagotrades Dec. 4 at 10:00 PM
$AIRE $LITM $PSTV $RANI amazing moves today mentioned many times these plays💰👌
0 · Reply
MGeronimo
MGeronimo Dec. 4 at 9:45 PM
$PSTV NEWS I HOPPED WAS COMING https://finviz.com/news/245317/plus-therapeutics-highlights-three-reyobiq-clinical-data-presentations-at-2025-wfnossno-annual-meeting
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 9:28 PM
$PSTV my 0.69 * 0.67 etc previous messages
0 · Reply
GoldenSteers
GoldenSteers Dec. 4 at 8:59 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $PURR.X $HIVE $PSTV $ARQQ State
0 · Reply
Redd_bull
Redd_bull Dec. 4 at 8:50 PM
$PSTV Very bullish
0 · Reply
LocalYokel1967
LocalYokel1967 Dec. 4 at 8:42 PM
$PSTV
0 · Reply
bambus3001
bambus3001 Dec. 4 at 8:42 PM
$PSTV das ist erst ein kleiner Hüpfer heute ,die grossen Sprünge werden kommen ,hoffe es kommt nicht zu schnell ein Buy Out.
0 · Reply
Latest News on PSTV
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 4, 2025, 7:30 AM EST - 9 hours ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Dec 1, 2025, 7:30 AM EST - 3 days ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 24, 2025, 7:30 AM EST - 10 days ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 20, 2025, 7:30 AM EST - 14 days ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 17, 2025, 7:30 AM EST - 17 days ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Nov 6, 2025, 7:30 AM EST - 4 weeks ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 30, 2025, 4:15 PM EDT - 5 weeks ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Oct 21, 2025, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 25, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 22, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 18, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:15 PM EDT - 3 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 26, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 18, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 15, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 4:15 PM EDT - 4 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Aug 14, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 31, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 23, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 15, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 10, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jul 8, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 26, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 4:15 PM EDT - 5 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Jun 25, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

Jun 24, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 30, 2025, 4:15 PM EDT - 6 months ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

May 23, 2025, 4:15 PM EDT - 6 months ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

May 14, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 7:00 AM EDT - 7 months ago

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Apr 23, 2025, 8:00 AM EDT - 8 months ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Apr 15, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:42 PM EDT - 8 months ago

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 27, 2025, 4:05 PM EDT - 9 months ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Mar 20, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Mar 19, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Mar 11, 2025, 11:00 AM EDT - 9 months ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Mar 10, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Mar 7, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Mar 6, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics Announces New Employment Inducement Grants

Mar 5, 2025, 4:01 PM EST - 9 months ago

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Mar 4, 2025, 2:06 PM EST - 9 months ago

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Feb 26, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Feb 24, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Feb 20, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Feb 18, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Dec 17, 2024, 7:30 AM EST - 1 year ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Dec 4, 2024, 7:30 AM EST - 1 year ago

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Dec 3, 2024, 7:30 AM EST - 1 year ago

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

GoldenBullys
GoldenBullys Dec. 4 at 10:10 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $PSTV $VALE $CSIQ $HON 5
0 · Reply
BennaG
BennaG Dec. 4 at 10:03 PM
$PSTV
0 · Reply
Mapagotrades
Mapagotrades Dec. 4 at 10:02 PM
$PSTV 😊😊😅
0 · Reply
Mapagotrades
Mapagotrades Dec. 4 at 10:00 PM
$AIRE $LITM $PSTV $RANI amazing moves today mentioned many times these plays💰👌
0 · Reply
MGeronimo
MGeronimo Dec. 4 at 9:45 PM
$PSTV NEWS I HOPPED WAS COMING https://finviz.com/news/245317/plus-therapeutics-highlights-three-reyobiq-clinical-data-presentations-at-2025-wfnossno-annual-meeting
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 9:28 PM
$PSTV my 0.69 * 0.67 etc previous messages
0 · Reply
GoldenSteers
GoldenSteers Dec. 4 at 8:59 PM
SNSE will SQUEEZE DON'T OVERLOOK IT!! $PURR.X $HIVE $PSTV $ARQQ State
0 · Reply
Redd_bull
Redd_bull Dec. 4 at 8:50 PM
$PSTV Very bullish
0 · Reply
LocalYokel1967
LocalYokel1967 Dec. 4 at 8:42 PM
$PSTV
0 · Reply
bambus3001
bambus3001 Dec. 4 at 8:42 PM
$PSTV das ist erst ein kleiner Hüpfer heute ,die grossen Sprünge werden kommen ,hoffe es kommt nicht zu schnell ein Buy Out.
0 · Reply
jesusatemylunch
jesusatemylunch Dec. 4 at 8:41 PM
$PSTV The dude abides (and we are all gonna enjoy some White Russians and bowling the way PSTV is blasting off) :)
0 · Reply
TradeMadeNow
TradeMadeNow Dec. 4 at 8:40 PM
$PSTV Christmas... Invest in companies that help humanity and make money. The next 2 years are going to be good here.
1 · Reply
flywithfitz81
flywithfitz81 Dec. 4 at 8:39 PM
$PSTV off we go
0 · Reply
Winning_calls
Winning_calls Dec. 4 at 8:39 PM
$PSTV 🤫🤫🤫🤞🤞🤞
0 · Reply
Nemonemo_712
Nemonemo_712 Dec. 4 at 8:37 PM
$PSTV 🚀🚀🚀🚀🚀🚀🚀🙏🏻🙏🏻🙏🏻🙏🏻
0 · Reply
Dennboy
Dennboy Dec. 4 at 8:35 PM
$PSTV The squeeze is starting and we have more eyes watching
0 · Reply
Rid2025
Rid2025 Dec. 4 at 8:34 PM
$PSTV any news
0 · Reply
Happy_Banner
Happy_Banner Dec. 4 at 8:34 PM
$PSTV
0 · Reply
MGeronimo
MGeronimo Dec. 4 at 8:26 PM
$PSTV SHE MAY RUN UP TO ABOUT $2.60 on any news or insider buying
0 · Reply
MGeronimo
MGeronimo Dec. 4 at 8:23 PM
$PSTV SHE WILL BREAK SMA 20 then 200 then run up on news or insider buying
0 · Reply
nobodyyk
nobodyyk Dec. 4 at 8:08 PM
$PSTV she is utilising the September 10th sacrifice
0 · Reply
Jbiv1971
Jbiv1971 Dec. 4 at 7:21 PM
$PSTV “the World Federation of Neuro-Oncology Societies/Society for Neuro-Oncology (WFNOS/SNO) Annual Meeting, November 19-23, 2025 in Honolulu, Hawaii.” This is from last month.
0 · Reply